Trial Profile
A phase I study of the safety, pharmacokinetic and pharmacodynamic properties of intravenously administered APG-1252 in patients with small cell lung cancer (SCLC) or other solid tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 29 Sep 2021
Price :
$35
*
At a glance
- Drugs Palcitoclax (Primary)
- Indications Small cell lung cancer; Solid tumours
- Focus Adverse reactions; First in man
- Acronyms APG-1252-AU-001
- Sponsors Jiangsu Ascentage Pharma
- 27 Sep 2021 Status changed from recruiting to completed.
- 24 Jan 2020 Planned End Date changed from 29 Feb 2020 to 29 Jan 2021.
- 13 Nov 2018 Pooled results from three phase I studies presented in an Ascentage Pharma media release.